0000950170-23-053817.txt : 20231017
0000950170-23-053817.hdr.sgml : 20231017
20231017174819
ACCESSION NUMBER: 0000950170-23-053817
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231013
FILED AS OF DATE: 20231017
DATE AS OF CHANGE: 20231017
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KASINGER JAMES R.
CENTRAL INDEX KEY: 0001708172
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 231330498
MAIL ADDRESS:
STREET 1: C/O CRISPR THERAPEUTICS, INC.
STREET 2: 610 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
ownership.xml
4
X0508
4
2023-10-13
0001674416
CRISPR Therapeutics AG
CRSP
0001708172
KASINGER JAMES R.
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
BOSTON
MA
02127
false
true
false
false
General Counsel and Secretary
false
Stock Option (Right to Buy)
44.31
2023-10-13
4
A
false
16667
0
A
2033-10-13
Common Shares
16667
16667
D
Restricted Stock Units
2023-10-13
4
A
false
6340
0
A
Common Shares
6340
6340
D
This option was granted on October 13, 2023 with respect to 16,667 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023.
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
2023-10-17